跳至主要内容

Huizhou Jizhong Biological Technology's Biological New Drug Obtained FDA Clinical Approval!

Recently, Huizhou Jizhong Biological Technology’s innovative drug local anesthetic injection - a new long-acting postoperative analgesic successfully obtained FDA (US Food and Drug Administration) new drug clinical trial approval!

The new long-acting postoperative analgesic was completed by Shanghai Medicilon in its full set of preclinical safety evaluation research, preclinical pharmacology, pharmacokinetics and other projects.

Huizhou Jizhong Biological Technology’s Biological New Drug Obtained FDA Clinical Approval!.webp

Anesthetics include general anesthetics, local anesthetics, narcotic analgesics, and muscle relaxants. Among them, local anesthetics are a class of drugs that are applied locally around nerve endings or nerve trunks, which can temporarily, completely and reversibly block the generation and conduction of nerve impulses, and temporarily disappear local pain sensation under conscious conditions. . Because local anesthetics are easy to use and have no damaging effects on various tissues, they have been widely recognized by clinicians. Currently, the commonly used local anesthetic drugs are procaine, lidocaine, bupivacaine and tetracaine. Huizhou Jizhong Biological Technology's new long-acting postoperative analgesic has obtained FDA's new drug clinical trial approval, which is a further development in accelerating the launch of new drugs, and will provide patients and medical staff with better medication options, which is of great clinical significance.

Medicilon’s full set of preclinical research services include API research and development, drug screening services, pharmaceutical preparations, pharmacology research services, pharmacokinetic research services, toxicology services, etc. There are currently 35 IND packages served by Medicilon have been approved by CFDA to enter clinical trials, 3 IND packages have been accepted by FDA and approved to enter clinical trials, 3 IND packages have been accepted by TGA and approved to enter clinical trials, and 1 IND Package has been accepted by EMA and approved to enter clinical trials.

Our Preclinical Pharmacokinetics Department has a number of professionals with rich theoretical knowledge and experimental experience for experiment design, experiment implementation, bioanalysis and data analysis. Our Pharmacokinetics Lab has passed the GLP certification by NMPA. Following the guiding principles of ICH, NMPA and FDA. The lab offers in vivo and in vitro pharmacokinetic tests according to the needs of our clients and provide them with complete sets of pharmacokinetic evaluation and optimization services. Our acclaimed quality data collection and efficient experiment can meet our clients’ needs from early drug discovery to new drug filing.

Medicilon has a quality management system for drug safety evaluation based on the internationally certified AAALAC quality standard and compliance with international and domestic GLP regulations.
Since 2008, we have continued to meet international standards and completed high-quality GLP safety evaluation services, establishing a long-term brand effect. Medicilon can perform systematic evaluation services covering multiple toxicity endpoints and has internationally recognized pathology studies to support our safety evaluation studies.

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文